『徳島大学 教育・研究者情報データベース (EDB)』---[学外] /
ID: Pass:

登録内容 (EID=392524)

EID=392524EID:392524, Map:0, LastModified:2023年3月2日(木) 11:30:54, Operator:[高山 哲治], Avail:TRUE, Censor:承認済, Owner:[高山 哲治], Read:継承, Write:継承, Delete:継承.
○種別 (必須): □学術論文 (審査論文) [継承]
○言語 (必須): □英語 [継承]
○招待 (推奨):
○審査 (推奨):
○カテゴリ (推奨):
○共著種別 (推奨):
○学究種別 (推奨):
○組織 (推奨):
○著者 (必須): 1.友成 哲
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨): □**** [ユーザ]
[継承]
2. (英) Tani Joji (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
3. (英) Ogawa Chikara (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
4. (英) Deguchi Akihiro (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
5. (英) Senoh Tomonori (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
6. (英) Moriya Akio (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
7.柴田 啓志
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
8. (英) Fukuno Hiroshi (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
9.田中 宏典 ([徳島大学.病院.先端医科医療開発研究プロジェクト]/[徳島大学.病院.診療科.内科.消化器内科])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨): □**** [ユーザ]
[継承]
10.田中 貴大
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨): □**** [ユーザ]
[継承]
11.谷口 達哉
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨): □**** [ユーザ]
[継承]
12.曽我部 正弘 ([徳島大学.キャンパスライフ健康支援センター])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨): □**** [ユーザ]
[継承]
13.河野 豊 ([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).実践地域診療・医科学])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
14. (英) Morishita Akihiro (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
15. (英) Takaguchi Koichi (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
16.宮本 弘志 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.消化器内科学]/[徳島大学.病院.診療科.内科.消化器内科])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
17.佐藤 康史 ([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).地域消化器・総合内科学])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
18. (英) Masaki Tsutomu (日) (読)
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
19.高山 哲治 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.消化器内科学])
○役割 (任意):
○貢献度 (任意):
○学籍番号 (推奨):
[継承]
○題名 (必須): □(英) Multicenter retrospective study of Initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.  (日)    [継承]
○副題 (任意):
○要約 (任意): □(英) Cabozantinib (CAB), a multiple kinase inhibitor, has been approved for use in patients with previously treated unresectable hepatocellular carcinoma (uHCC). However, real-world clinical data are lacking, particularly clinical data regarding dose modifications of CAB. We analyzed the clinical outcomes of CAB in uHCC and compared treatment outcomes between the full- and reduced-dose groups. This multicenter, observational study included patients with uHCC who were treated with CAB from March 2021 to April 2022. Patient characteristics, efficacy, and safety were compared between the full- and reduced-dose groups. Twenty-six patients from eight institutes were analyzed. Cabozantinib was administered as a third-line or later treatment in 25 (96.2%) patients and postimmunotherapy in 21 (80.5%) patients. There were 15 patients in the full-dose group (60 mg CAB) and 11 in the reduced-dose group (40 or 20 mg CAB). The objective response rate (ORR) and disease control rate (DCR) were not significantly different between the two groups. The ORR was 6.7% for the full-dose group and 9.1% for the reduced-dose group, and the DCR was 53.4% and 81.8%, respectively. Progression-free survival analysis showed no significant differences between the two groups. The incidence of decreased appetite, fatigue, and diarrhea, and the rate of discontinuation and dose reduction, was significantly higher in the full-dose group. Our study suggests that the efficacy and safety of CAB in real-world clinical practice are comparable to those of the phase III trial (CELESTIAL), and that dose reduction of CAB may be a safer treatment option.  (日)    [継承]
○キーワード (推奨):
○発行所 (推奨):
○誌名 (必須): □Hepatology Research (日本肝臓学会)
(pISSN: 1386-6346, eISSN: 1872-034X)

○ISSN (任意): □1386-6346
ISSN: 1386-6346 (pISSN: 1386-6346, eISSN: 1872-034X)
Title: Hepatology research : the official journal of the Japan Society of Hepatology
Title(ISO): Hepatol Res
Supplier: Japan Society of Hepatology
Publisher: Wiley Publishing
 (NLM Catalog)   (医中誌Web)   (Wiley)   (Scopus)   (CrossRef)  (Scopus information is found. [need login])
[継承]
[継承]
○巻 (必須): □53 [継承]
○号 (必須): □2 [継承]
○頁 (必須): □172 178 [継承]
○都市 (任意):
○年月日 (必須): □西暦 2023年 2月 初日 (令和 5年 2月 初日) [継承]
○URL (任意):
○DOI (任意): □10.1111/hepr.13845    (→Scopusで検索) [継承]
○PMID (任意): □36214071    (→Scopusで検索) [継承]
○CRID (任意):
○WOS (任意):
○Scopus (任意):
○評価値 (任意):
○被引用数 (任意):
○指導教員 (推奨):
○備考 (任意): 1.(英) Article.ELocationID: 10.1111/hepr.13845  (日)    [継承]
2.(英) Article.PublicationTypeList.PublicationType: Journal Article  (日)    [継承]
3.(英) KeywordList.Keyword: cabozantinib  (日)    [継承]
4.(英) KeywordList.Keyword: hepatocellular carcinoma  (日)    [継承]

標準的な表示

和文冊子 ● Tetsu Tomonari, Joji Tani, Chikara Ogawa, Akihiro Deguchi, Tomonori Senoh, Akio Moriya, Hiroshi Shibata, Hiroshi Fukuno, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Yutaka Kawano, Akihiro Morishita, Koichi Takaguchi, Hiroshi Miyamoto, Yasushi Sato, Tsutomu Masaki and Tetsuji Takayama : Multicenter retrospective study of Initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma., Hepatology Research, Vol.53, No.2, 172-178, 2023.
欧文冊子 ● Tetsu Tomonari, Joji Tani, Chikara Ogawa, Akihiro Deguchi, Tomonori Senoh, Akio Moriya, Hiroshi Shibata, Hiroshi Fukuno, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Yutaka Kawano, Akihiro Morishita, Koichi Takaguchi, Hiroshi Miyamoto, Yasushi Sato, Tsutomu Masaki and Tetsuji Takayama : Multicenter retrospective study of Initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma., Hepatology Research, Vol.53, No.2, 172-178, 2023.

関連情報

Number of session users = 1, LA = 0.64, Max(EID) = 417133, Max(EOID) = 1129774.